To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
251 Current newsrss
International antibiotics study: HZI receives €6m funding
pharmaceutical company GlaxoSmithKline, is still known by its rather cryptic working name, GSK1322322. In the course of clinical trials to evaluate new drugs, physicians typically end up with large numbers...
Priaxon announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary...
£10m in milestone payments received from GlaxoSmithKline
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055, ...
Executive Team of GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in Wavre, Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of BESIX, IBA...
that Abbott has announced in the last 12 months with a leading pharmaceutical company. Recent collaborations with Pfizer, GlaxoSmithKline and Merck focus on the development of companion diagnostic tests for use...
Janssen Biologics announced it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK). Sirukumab is a human anti...
this pathway, MEK inhibitors (MEKi’s) may be able to combat resistance to BRAF inhibitors.At the 2012 ASCO annual meeting, data was presented from GlaxoSmithKline’s (GSK) Phase I/II clinical trial evaluating...
KineMed, Inc. enters multi-year agreement with GlaxoSmithKline to develop kinetic biomarkers
KineMed, Inc. announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK...